MX2023002533A - Composiciones y metodos para proteger contra patogenos e irritantes transportados por el aire. - Google Patents

Composiciones y metodos para proteger contra patogenos e irritantes transportados por el aire.

Info

Publication number
MX2023002533A
MX2023002533A MX2023002533A MX2023002533A MX2023002533A MX 2023002533 A MX2023002533 A MX 2023002533A MX 2023002533 A MX2023002533 A MX 2023002533A MX 2023002533 A MX2023002533 A MX 2023002533A MX 2023002533 A MX2023002533 A MX 2023002533A
Authority
MX
Mexico
Prior art keywords
compositions
methods
irritants
protecting against
airborne pathogens
Prior art date
Application number
MX2023002533A
Other languages
English (en)
Inventor
Nazlie Latefi
Original Assignee
Applied Biological Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Biological Laboratories Inc filed Critical Applied Biological Laboratories Inc
Publication of MX2023002533A publication Critical patent/MX2023002533A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción presenta métodos y composiciones para incrementar la capacidad de las membranas respiratorias para filtrar patógenos transportados por el aire y proteger a un individuo contra infecciones respiratorias que resultan de la inhalación de dichos patógenos. En particular, la descripción provee composiciones anti-microbianas que previenen y tratan las infecciones respiratorias causadas por bacterias, hongos, virus.
MX2023002533A 2016-02-25 2018-08-23 Composiciones y metodos para proteger contra patogenos e irritantes transportados por el aire. MX2023002533A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662299775P 2016-02-25 2016-02-25

Publications (1)

Publication Number Publication Date
MX2023002533A true MX2023002533A (es) 2023-03-14

Family

ID=59679209

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018010198A MX2018010198A (es) 2016-02-25 2017-02-24 Composiciones y metodos para proteger contra patogenos e irritantes transportados por el aire.
MX2023002533A MX2023002533A (es) 2016-02-25 2018-08-23 Composiciones y metodos para proteger contra patogenos e irritantes transportados por el aire.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018010198A MX2018010198A (es) 2016-02-25 2017-02-24 Composiciones y metodos para proteger contra patogenos e irritantes transportados por el aire.

Country Status (13)

Country Link
US (2) US20170246262A1 (es)
EP (1) EP3419629A4 (es)
JP (2) JP7071933B2 (es)
KR (1) KR20180120204A (es)
CN (2) CN109069520A (es)
AU (1) AU2017224113B2 (es)
BR (1) BR112018067914A2 (es)
CA (1) CA3014764A1 (es)
IL (1) IL261345B (es)
MX (2) MX2018010198A (es)
SG (1) SG11201806868TA (es)
WO (1) WO2017147540A1 (es)
ZA (1) ZA201805615B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170360815A1 (en) * 2016-02-25 2017-12-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
US10596105B2 (en) * 2017-06-29 2020-03-24 Max Spielberg Organic nasal treatment solution
CN110354262A (zh) * 2018-04-23 2019-10-22 杭州索契健康科技有限公司 一种片剂型的n-乙酰神经氨酸抗病毒组合物
JP7351296B2 (ja) * 2018-04-27 2023-09-27 ライオン株式会社 口腔内菌叢改善剤及び口腔用組成物
CN112439055A (zh) * 2019-08-29 2021-03-05 湘北威尔曼制药股份有限公司 用于预防或治疗尿酸性疾病的组合物
JPWO2021079921A1 (es) * 2019-10-25 2021-04-29
IT202000005026A1 (it) * 2020-03-09 2021-09-09 Sofar Spa Lattoferrina per uso inalatorio ad azione antivirale
IT202000005011A1 (it) * 2020-03-09 2021-09-09 Sofar Spa Lattoferrina per uso orale ad azione antivirale
IT202100002003A1 (it) * 2021-02-01 2022-08-01 Plumestars S R L Nuove composizioni antivirali e loro utilizzo in terapia e nel trattamento di infezioni virali
CN117202795A (zh) * 2021-04-06 2023-12-08 约翰·卡佩勒里 婴儿配方奶粉
CN115886073A (zh) * 2022-04-01 2023-04-04 北京三元食品股份有限公司 一种发酵乳
US20230321158A1 (en) * 2022-04-08 2023-10-12 Holista Biotech Sdn Bhd Compositions for protection against pathogen infection and method thereof

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051231A (en) 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
ATE186552T1 (de) 1988-09-01 1999-11-15 Bayer Ag Menschliches rhinovirusrezeptorprotein, das die virusinfektionsanfälligkeit hemmt
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US20010053359A1 (en) 1994-07-26 2001-12-20 Peter Watts Drug delivery composition for the nasal administration of antiviral agents
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5879712A (en) 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
IL115199A (en) 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition
AU2911197A (en) 1996-05-24 1998-01-05 Imperial College Of Science, Technology And Medicine Polycationic sterol derivatives as transfection agents
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US20030229040A1 (en) 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
IT1291366B1 (it) 1997-05-14 1999-01-07 Angelini Ricerche Spa Composizione farmaceutica antivirale comprendente acido glicirrizico ed almeno una proteina dotata di attivita' antivirale
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6887906B1 (en) 1997-07-01 2005-05-03 Isispharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
WO1999004819A1 (en) 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
US6225118B1 (en) 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
US7229841B2 (en) 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6080783A (en) 1998-09-01 2000-06-27 Gum Tech International, Inc. Method and composition for delivering zinc to the nasal membrane
US6093417A (en) * 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
PT1811036E (pt) 1999-02-22 2011-07-11 Univ Georgetown Imunolipossomas dirigidos por fragmento de anticorpo para distribuição sistémica de genes
US6365156B1 (en) * 1999-04-16 2002-04-02 Osel, Inc. Method for improving the half-life of soluble viral-specific ligands on mucosal membranes
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
US6200599B1 (en) 1999-10-07 2001-03-13 The Regents Of The University Of California Ortho ester lipids
US20050037086A1 (en) 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
EP1267834A4 (en) 2000-03-29 2003-08-27 Aradigm Corp CATIONIC LIPOSOMES
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
ES2263643T3 (es) * 2000-07-28 2006-12-16 Immupharm Aps Uso de hidroxietilrutosidos para el tratamiento de los sintomas del r esfriado comun, de la fiebre de heno y de infecciones relacionadas con el tacto respiratorio.
US7045159B1 (en) 2000-09-19 2006-05-16 Rutgers, The State University Of New Jersey Antiviral substances from plant cuticular and epiciticular material
ES2728168T3 (es) 2000-12-01 2019-10-22 Max Planck Gesellschaft Moléculas pequeñas de ARN que median en la interferencia de ARN
CA2442261A1 (en) 2001-03-26 2002-10-03 Alza Corporation Liposome composition for improved intracellular delivery of a therapeutic agent
US20020192274A1 (en) 2001-03-26 2002-12-19 Ponnappa Biddanda C. pH sensitive liposomal drug delivery
GB2374008B (en) * 2001-04-04 2005-03-16 John Carter Pharmaceutical compositions comprising copper and zinc
US20030026831A1 (en) 2001-04-20 2003-02-06 Aparna Lakkaraju Anionic liposomes for delivery of bioactive agents
JP2004535388A (ja) 2001-04-30 2004-11-25 ターゲティッド ジェネティクス コーポレイション 脂質含有薬物送達複合体およびそれらの生成方法
US7166435B2 (en) 2001-08-06 2007-01-23 The Quigley Corporation Compositions and methods for reducing the transmissivity of illnesses
US7063860B2 (en) 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
AU2002365083A1 (en) 2001-10-17 2003-06-30 Ganado Research, L.L.C. Composition and method to treat viral bacterial and parasitic infections and infestations
DE10152145A1 (de) 2001-10-19 2003-05-22 Novosom Ag Stabilisierung von Liposomen und Emulsionen
WO2003041723A1 (de) 2001-11-12 2003-05-22 Reinmueller Johannes Pharmazeutische anwendungen von hyaluronsäure-präparaten
JP2005538033A (ja) 2001-12-04 2005-12-15 ナノスペクトラ バイオサイエンセズ，インク． 過剰なあるいは不適切な新脈管形成によって特徴付けられる病状の治療
WO2003057190A1 (en) 2001-12-31 2003-07-17 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
US20060058249A1 (en) 2002-01-09 2006-03-16 Shangguan Tong Efficient nucleic acid encapsulation into medium sized liposomes
WO2003068934A2 (en) * 2002-02-14 2003-08-21 Rutter William J Chimeric molecules for cleavage in a treated host
DE10207177A1 (de) 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
US7037520B2 (en) 2002-03-22 2006-05-02 Baylor College Of Medicine Reversible masking of liposomal complexes for targeted delivery
AU2003233464A1 (en) 2002-03-29 2003-10-13 Bristol-Myers Squibb Corporation Lipid mediated screening of drug candidates for identification of active compounds
AU2003237686A1 (en) 2002-05-24 2003-12-12 Max-Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. Rna interference mediating small rna molecules
US8211448B2 (en) 2003-07-07 2012-07-03 Nares Ab Microemulsions and its use for preventing airway diseases
US20050277610A1 (en) 2004-03-15 2005-12-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
WO2006085987A2 (en) 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
US20070135377A1 (en) 2004-12-10 2007-06-14 Roman Stephen B Thixotropic anti-viral formulation
CN100493605C (zh) 2005-01-07 2009-06-03 安米 人溶菌酶在制备抗流行性感冒病毒药物中的应用
US8679484B2 (en) 2005-03-02 2014-03-25 Polyrizon Ltd. Method for removal of toxins from mucosal membranes
US8999406B2 (en) 2005-07-26 2015-04-07 Global Life Technologies Corp. Antimicrobial and antiviral composition
US20090011042A1 (en) 2005-07-26 2009-01-08 Global Life Technologies, Corp Antimicrobial and antiviral composition
US20070026085A1 (en) 2005-07-26 2007-02-01 Global Life Technologies Corp. Antimicrobial and antiviral composition
EP3144324A1 (en) 2006-06-02 2017-03-22 Synedgen, Inc. Chitosan-derivative compounds and methods of controlling microbial populations
KR20100061441A (ko) 2007-07-06 2010-06-07 래크리드 인코포레이티드 기도 내 생물막을 용해시키기 위한 가수분해 및 산화효소의 용도
EP2060257A1 (en) 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
BRPI0917773B1 (pt) 2008-12-26 2019-02-05 Nbc Meshtec Inc estrutura fibrosa antiviral
KR101119538B1 (ko) 2009-06-10 2012-02-22 장선호 시알릭산-함유 유청 단백질을 유효성분으로 함유하는 인플루엔자 바이러스 감염증의 예방 및 치료용 조성물
JP5018839B2 (ja) 2009-07-22 2012-09-05 株式会社村田製作所 誘電体セラミックおよび積層セラミックコンデンサ
CA2779532C (en) 2009-12-22 2018-05-22 Marinomed Biotechnologie Gmbh Synergistic antiviral composition and use thereof
CN103025346A (zh) 2010-04-23 2013-04-03 普若拜特有限公司 感冒治疗
CN101966285B (zh) * 2010-10-13 2012-05-23 郑州后羿制药有限公司 一种防治鸡呼吸道疾病的中药、中药气雾剂及其生产方法
JP5730041B2 (ja) 2011-01-28 2015-06-03 日本ゼトック株式会社 口腔用組成物
WO2012142492A2 (en) 2011-04-15 2012-10-18 University Of Georgia Research Foundation, Inc. Methods for inhibiting virus replication
US20130028882A1 (en) 2011-07-07 2013-01-31 Humanitas Technology, LLC Antiviral compositions and methods of their use
FR2980974B1 (fr) 2011-10-10 2014-02-21 Alaxia Composition comprenant un sel d'hypothiocyanite d'un cation alcalin, a l'etat solide
EP2845606B1 (en) * 2014-07-10 2018-09-05 Symrise AG Medicament for the prevention, curing or abating cough and inflammations of the respiratory system

Also Published As

Publication number Publication date
JP2019506460A (ja) 2019-03-07
AU2017224113A1 (en) 2018-09-06
CN109069520A (zh) 2018-12-21
JP7458438B2 (ja) 2024-03-29
CA3014764A1 (en) 2017-08-31
EP3419629A4 (en) 2019-10-30
RU2018133581A3 (es) 2020-08-11
US20220218798A9 (en) 2022-07-14
US20210052710A1 (en) 2021-02-25
MX2018010198A (es) 2019-06-12
WO2017147540A1 (en) 2017-08-31
ZA201805615B (en) 2019-11-27
IL261345B (en) 2022-04-01
RU2018133581A (ru) 2020-03-25
JP2022115999A (ja) 2022-08-09
JP7071933B2 (ja) 2022-05-19
SG11201806868TA (en) 2018-09-27
IL261345A (en) 2018-10-31
CN117942405A (zh) 2024-04-30
BR112018067914A2 (pt) 2019-01-29
AU2017224113B2 (en) 2022-04-21
KR20180120204A (ko) 2018-11-05
US20170246262A1 (en) 2017-08-31
EP3419629A1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
MX2023002533A (es) Composiciones y metodos para proteger contra patogenos e irritantes transportados por el aire.
DK3313422T3 (da) Sammensætninger omfattende en bakteriestamme af blautia hydrogenotrophica til anvendelse i behandlingen eller forebyggelsen af diarré eller forstoppelse
PH12017501578A1 (en) Fungicidally active compound combinations
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
MX2019002978A (es) Composiciones que comprenden una bacteria no patogena y metodos para proteger plantas y animales anfitriones contra enfermedades micoticas, bacterianas y virales.
EP3903823A3 (en) Antimicrobial peptides and methods of use thereof
PH12016502002B1 (en) Novel bacteriophage and composition comprising same
SG11202002376YA (en) Compositions and methods for protecting against airborne pathogens and irritants
PH12017501136A1 (en) Active compound combinations
PH12017501135A1 (en) Active compound combinations
PH12017501137A1 (en) Active compound combinations
MX2016014853A (es) Aplicaciones volatiles contra patogenos.
PH12016502001A1 (en) Novel bacteriophage and composition comprising same
UY36432A (es) Combinaciones de compuestos activos que comprenden un derivado de (tio) carboxamida y compuesto(s) fungicida(s)
MY189342A (en) Treatment and prevention of the common cold using povidone-iodine
MX2015011198A (es) Compuestos antivirales.
WO2013152274A8 (en) Epitope- scaffold immunogens against respiratory syncytial virus (rsv)
MA39955A (fr) Compositions désinfectantes et antimicrobiennes, en particulier pour le domaine vétérinaire
EA201401202A1 (ru) ВАКЦИНАЦИЯ РЕСПИРАТОРНЫМ КОРОНАВИРУСОМ СОБАК ДЛЯ ЗАЩИТЫ ОТ ИНФЕКЦИЙ B.Bronchiseptica
PH12016502000A1 (en) Novel bacteriophage and composition comprising same
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
EP3725320C0 (en) COMPOSITION COMPRISING A STRAIN OF AGATHOBACULUM SP. AS AN ACTIVE INGREDIENT FOR THE PREVENTION, MITIGATION OR TREATMENT OF AN AUTISM SPECTRUM DISORDER
PH12017501943A1 (en) Influenza virus neutralizing peptidomimetic compounds
MX2018000384A (es) Composiciones para el tratamiento contra infecciones.
MX2015010892A (es) Compuestos antivirales.